Neuroprotective agents for the treatment of acute ischemic stroke

Bruce Ovbiagele, Stella Kidwell, Sidney Starkman, Jeffrey L. Saver

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Neuroprotective treatments are therapies designed to interrupt the cellular, biochemical, and metabolic elaboration of injury during or following exposure to ischemia; they encompass a rapidly expanding array of pharmacologic interventions. Various classes of neuroprotective agents have reached phase III efficacy trials in focal ischemic stroke, but none has proven effective, despite successful preceding animal studies. This notwithstanding, recent favorable results of hypothermia in human cardiac arrest trials have validated the general concept of neuroprotection. In addition, the promise of neuroprotective therapy for focal acute ischemic stroke has been renewed by innovations in strategies of preclinical drug development and clinical trial design that rectify past defects, including trial testing of combination therapies rather than single agents and novel approaches to accelerating time to initiation of experimental treatment.

Original languageEnglish (US)
Pages (from-to)9-20
Number of pages12
JournalCurrent Neurology and Neuroscience Reports
Volume3
Issue number1
StatePublished - Jan 2003
Externally publishedYes

Fingerprint

Neuroprotective Agents
Stroke
Heart Arrest
Hypothermia
Therapeutics
Ischemia
Clinical Trials
Wounds and Injuries
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Neuroprotective agents for the treatment of acute ischemic stroke. / Ovbiagele, Bruce; Kidwell, Stella; Starkman, Sidney; Saver, Jeffrey L.

In: Current Neurology and Neuroscience Reports, Vol. 3, No. 1, 01.2003, p. 9-20.

Research output: Contribution to journalArticle

Ovbiagele, Bruce ; Kidwell, Stella ; Starkman, Sidney ; Saver, Jeffrey L. / Neuroprotective agents for the treatment of acute ischemic stroke. In: Current Neurology and Neuroscience Reports. 2003 ; Vol. 3, No. 1. pp. 9-20.
@article{89954368379040fead44495c6fcb695e,
title = "Neuroprotective agents for the treatment of acute ischemic stroke",
abstract = "Neuroprotective treatments are therapies designed to interrupt the cellular, biochemical, and metabolic elaboration of injury during or following exposure to ischemia; they encompass a rapidly expanding array of pharmacologic interventions. Various classes of neuroprotective agents have reached phase III efficacy trials in focal ischemic stroke, but none has proven effective, despite successful preceding animal studies. This notwithstanding, recent favorable results of hypothermia in human cardiac arrest trials have validated the general concept of neuroprotection. In addition, the promise of neuroprotective therapy for focal acute ischemic stroke has been renewed by innovations in strategies of preclinical drug development and clinical trial design that rectify past defects, including trial testing of combination therapies rather than single agents and novel approaches to accelerating time to initiation of experimental treatment.",
author = "Bruce Ovbiagele and Stella Kidwell and Sidney Starkman and Saver, {Jeffrey L.}",
year = "2003",
month = "1",
language = "English (US)",
volume = "3",
pages = "9--20",
journal = "Current Neurology and Neuroscience Reports",
issn = "1528-4042",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Neuroprotective agents for the treatment of acute ischemic stroke

AU - Ovbiagele, Bruce

AU - Kidwell, Stella

AU - Starkman, Sidney

AU - Saver, Jeffrey L.

PY - 2003/1

Y1 - 2003/1

N2 - Neuroprotective treatments are therapies designed to interrupt the cellular, biochemical, and metabolic elaboration of injury during or following exposure to ischemia; they encompass a rapidly expanding array of pharmacologic interventions. Various classes of neuroprotective agents have reached phase III efficacy trials in focal ischemic stroke, but none has proven effective, despite successful preceding animal studies. This notwithstanding, recent favorable results of hypothermia in human cardiac arrest trials have validated the general concept of neuroprotection. In addition, the promise of neuroprotective therapy for focal acute ischemic stroke has been renewed by innovations in strategies of preclinical drug development and clinical trial design that rectify past defects, including trial testing of combination therapies rather than single agents and novel approaches to accelerating time to initiation of experimental treatment.

AB - Neuroprotective treatments are therapies designed to interrupt the cellular, biochemical, and metabolic elaboration of injury during or following exposure to ischemia; they encompass a rapidly expanding array of pharmacologic interventions. Various classes of neuroprotective agents have reached phase III efficacy trials in focal ischemic stroke, but none has proven effective, despite successful preceding animal studies. This notwithstanding, recent favorable results of hypothermia in human cardiac arrest trials have validated the general concept of neuroprotection. In addition, the promise of neuroprotective therapy for focal acute ischemic stroke has been renewed by innovations in strategies of preclinical drug development and clinical trial design that rectify past defects, including trial testing of combination therapies rather than single agents and novel approaches to accelerating time to initiation of experimental treatment.

UR - http://www.scopus.com/inward/record.url?scp=0042888736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042888736&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 9

EP - 20

JO - Current Neurology and Neuroscience Reports

JF - Current Neurology and Neuroscience Reports

SN - 1528-4042

IS - 1

ER -